Research Topics

Genomes and Genes

systemic scleroderma

Summary

Alias: systemic sclerosis
Summary: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.

Webpages

  1. final diagnosis -- case 428
    path.upmc.edu/cases/case428/dx.html
  2. research - division of rheumatology and clinical immunology at the university of pittsburgh department of medicine
    www.dept-med.pitt.edu/Rheum/research.html
  3. scleroderma program: classification of scleroderma
    www.med.umich.edu/scleroderma/patients/classification.htm
  4. rheumatology at great ormond street hospital
    www.ich.ucl.ac.uk/website/gosh/clinicalservices/Rheumatology ...
  5. scleroderma
    www.chw.org/display/PPF/DocID/21658/router.asp
  6. scleroderma
    www.chw.org/display/PPF/DocID/21658/router.asp#1658
  7. rheumatology at great ormond street hospital
    www.ich.ucl.ac.uk/gosh/clinicalservices/Rheumatology/Medical ...
  8. uams biochemistry faculty - grover paul miller, ph.d
    www.uams.edu/biochem/miller.asp
  9. sjogrens syndrome - symptoms - diagnosis - treatment
    www.hopkins-arthritis.som.jhmi.edu/other/sjogrens.html
  10. faculty profile
    lifesciences.umaryland.edu/faculty/default.asp?ID=112

Research Grants

  1. Clinical Component
    Brian L Kotzin; Fiscal Year: 2003
  2. Mediators of Fibrosis in Scleroderma Skin and Lung
    Carol A Feghali-Bostwick; Fiscal Year: 2008
  3. A LINKAGE STUDY IN FAMILIAL PULMONARY FIBROSIS
    Mark P Steele; Fiscal Year: 2004
  4. Oral Health in People with Systemic Sclerosis
    Hon K Yuen; Fiscal Year: 2008
  5. The role of IGF-II in scleroderma-associated pulmonary fibrosis
    Eileen Hsu; Fiscal Year: 2008
  6. Oral Health in People with Systemic Sclerosis
    Hon K Yuen; Fiscal Year: 2007
  7. Systemic Lupus Erythmatosus and Other Autoimmune Disease
    Glinda S Cooper; Fiscal Year: 2005
  8. T Cells in the Pathogenesis of Systemic Sclerosis
    Chris D Platsoucas; Fiscal Year: 2005
  9. T Cells in the Pathogenesis of Systemic Sclerosis
    Chris D Platsoucas; Fiscal Year: 2005
  10. Mediators of Fibrosis in Scleroderma Skin and Lung
    Carol A Feghali-Bostwick; Fiscal Year: 2006

Publications

  1. [Pulmonary arterial hypertension in connective tissue disease]
    V Cottin
    Service de Pneumologie, Centre de référence des maladies orphelines pulmonaires, Hôpital Louis Pradel, Hospices Civils de Lyon, Université de Lyon, UMR 754 INRA ENVL UCBL IFR128, Lyon, France
    Rev Mal Respir 23:13S61-72
  2. Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis
    M Hasegawa
    Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13 1 Takaramachi, Kanazawa, Ishikawa 920 8641, Japan
    Ann Rheum Dis 63:1514-7
  3. Acute congestive heart failure associated with a limited form of systemic sclerosis and primary biliary cirrhosis
    T Shinohara
    Internal Medicine I, National Defense Medical College, Tokorozawa, Saitama
    Intern Med 40:73-6
  4. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin
    Z Mackiewicz
    Institute of Experimental and Clinical Medicine, Vilnius, Lithuania
    Clin Exp Rheumatol 20:641-6
  5. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis
    C Nishijima
    Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
    Clin Exp Immunol 138:357-63
  6. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma
    Ayumi Yoshizaki
    Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, 1 7 1 Sakamoto, Nagasaki, 852 8501, Japan
    Am J Pathol 172:1650-63
  7. [Pathogenesis of systemic sclerosis]
    M Fabri
    Klinik und Poliklinik für Dermatologie und Venerologie, Universität zu Köln, Kerpenerstrasse 62, 50924, Köln, Germany
    Hautarzt 58:838, 840-3
  8. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years
    L Bettoni
    Servizio di Reumatologia ed Immunologia Clinica, Spedali Civili and University, I-25124 Brescia, Italy
    Clin Rheumatol 21:244-50
  9. [Fourier transform spectral analysis of cutaneous blood flux in systemic sclerosis]
    M Salvat Melis
    Laboratoire HP2 EA 3745, Inserm ERI 017, université de Grenoble 1 EA 3745, CHU de Grenoble, 38043 Grenoble Cedex 09, France
    J Mal Vasc 32:83-9
  10. [Antiphospholipid syndrome in patients with systemic connective tissue diseases]
    Dalia Unikiene
    Clinic of Rheumatology, Kaunas University of Medicine, Lithuania
    Medicina (Kaunas) 39:454-9

Scientific Experts

Detail Information

Webpages66 found, 30 most recent shown here

  1. final diagnosis -- case 428
    path.upmc.edu/cases/case428/dx.html
  2. research - division of rheumatology and clinical immunology at the university of pittsburgh department of medicine
    www.dept-med.pitt.edu/Rheum/research.html
  3. scleroderma program: classification of scleroderma
    www.med.umich.edu/scleroderma/patients/classification.htm
  4. rheumatology at great ormond street hospital
    www.ich.ucl.ac.uk/website/gosh/clinicalservices/Rheumatology ...
  5. scleroderma
    www.chw.org/display/PPF/DocID/21658/router.asp
  6. scleroderma
    www.chw.org/display/PPF/DocID/21658/router.asp#1658
  7. rheumatology at great ormond street hospital
    www.ich.ucl.ac.uk/gosh/clinicalservices/Rheumatology/Medical ...
  8. uams biochemistry faculty - grover paul miller, ph.d
    www.uams.edu/biochem/miller.asp
  9. sjogrens syndrome - symptoms - diagnosis - treatment
    www.hopkins-arthritis.som.jhmi.edu/other/sjogrens.html
  10. faculty profile
    lifesciences.umaryland.edu/faculty/default.asp?ID=112
  11. rheumatology at great ormond street hospital
    www.ich.ucl.ac.uk/gosh/clinicalservices/Rheumatology/Medical ...
  12. scleroderma research publications - johns hopkins scleroderma center
    scleroderma.jhmi.edu/research/publications.html
  13. radiology, university of rochester medical center
    www.urmc.rochester.edu/smd/Rad/neurocases/Neuro1101.htm
  14. for patients and families - med - peds - rheumatology, university of minnesota
    www.med.umn.edu/peds/rheum/patients/home.html
  15. training at the university of kentucky college of medicine division of rheumatology
    www.mc.uky.edu/rheumatology/education/resident-curric.asp
  16. new page 3
    www.utmb.edu/gcrc/research/CenterBibliography.htm
  17. scleroderma
    www.childrens.com/HealthLibrary/HealthLibContent.cfm?pageid= ...
  18. immunotechnology: affinity proteomics - antibody microarray-based high throughput proteome analysis
    www.immun.lth.se/research/immunotechnology/affinity_proteomi ...
  19. university of florida department of medicine
    www.medicine.ufl.edu/rheuma/rheuma_faculty.asp
  20. anti-caspase-8 autoantibody response in silicosis patients is associated with hla-drb1, dqb1 and dpb1 alleles
    joh.med.uoeh-u.ac.jp/e/E/47/E47_1_05.html
  21. pulmonary fibrosis
    www.hmc.psu.edu/healthinfo/pq/pulmonaryfibrosis.htm
  22. scleroderma treatment - johns hopkins
    scleroderma.jhmi.edu/patients/treatment-options.html
  23. university of pittsburgh gsph idm faculty- albert d. donnenberg, phd
    www.idm.pitt.edu/faculty/donnenberg.html
  24. our physicians - health information
    www.memorialhealth.com/healthinfo/content.aspx?pageid=P01729
  25. medical genetics ][ internal medicine ][ the university of texas medical school at houston
    www.uth.tmc.edu/schools/med/imed/divisions/medical-genetics/ ...
  26. acta medica okayama
    escholarship.lib.okayama-u.ac.jp/amo/vol50/iss6/
  27. gastroparesis
    www.clarian.org/ADAM/doc/HealthIllustratedEncyclopedia/1/000 ...
  28. connective tissue growth factor - fibrogen, inc
    www.fibrogen.com/ctgf

Research Grants62

  1. Clinical Component
    Brian L Kotzin; Fiscal Year: 2003
    ..investigation on type 1 diabetes, systemic lupus erythematosus and lupus nephritis, rheumatoid arthritis, systemic sclerosis, multiple sclerosis, autoimmune pulmonary diseases including interstitial lung disease and granulomatous ..
  2. Mediators of Fibrosis in Scleroderma Skin and Lung
    Carol A Feghali-Bostwick; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) is an idiopathic connective tissue disease of unknown etiology that leads to debilitating and life-threatening fibrosis...
  3. A LINKAGE STUDY IN FAMILIAL PULMONARY FIBROSIS
    Mark P Steele; Fiscal Year: 2004
    ..pulmonary fibrosis is frequently observed in autoimmune disease, including rheumatoid arthritis and systemic sclerosis; variable susceptibility is evident among workers who are reported to be exposed occupationally to similar ..
  4. Oral Health in People with Systemic Sclerosis
    Hon K Yuen; Fiscal Year: 2008
    ..health status, oral health- related behaviors, and quality of life in the US population of patients with systemic sclerosis (scleroderma or SSc)...
  5. The role of IGF-II in scleroderma-associated pulmonary fibrosis
    Eileen Hsu; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and multiple internal organs...
  6. Oral Health in People with Systemic Sclerosis
    Hon K Yuen; Fiscal Year: 2007
    ..health status, oral health- related behaviors, and quality of life in the US population of patients with systemic sclerosis (scleroderma or SSc)...
  7. Systemic Lupus Erythmatosus and Other Autoimmune Disease
    Glinda S Cooper; Fiscal Year: 2005
    ..for Lupus - a prospective analysis using data from the Nurses' Health Study (I and II) 3) Parity and Risk of Systemic Sclerosis - an analysis using a unique resource, the hospitalization and pregnancy registries covering the entire ..
  8. T Cells in the Pathogenesis of Systemic Sclerosis
    Chris D Platsoucas; Fiscal Year: 2005
    DESCRIPTION (provided by applicant): Systemic Sclerosis (SSc) is a chronic disease characterized by extensive fibrosis, microvascular fibrointimal proliferation and autoantibody production...
  9. T Cells in the Pathogenesis of Systemic Sclerosis
    Chris D Platsoucas; Fiscal Year: 2005
    DESCRIPTION (provided by applicant): Systemic Sclerosis (SSc) is a chronic disease characterized by extensive fibrosis, microvascular fibrointimal proliferation and autoantibody production...
  10. Mediators of Fibrosis in Scleroderma Skin and Lung
    Carol A Feghali-Bostwick; Fiscal Year: 2006
    DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology that affects mostly women and is associated with significant morbidity and mortality...
  11. Role of Caveolin in Scleroderma Tissue Fibrosis and Vasculopathy
    Sergio A Jimenez; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by widespread fibroproliferative vascular damage and progressive tissue fibrosis leading to severe multi-organ dysfunction...
  12. VASCULOPATHY, APOPTOSIS AND AUTOIMMUNITY
    Joseph M Ahearn; Fiscal Year: 2003
    ..upon the molecular mechanism by which vasculopathy leads to fibrotic and autoimmune manifestations of systemic sclerosis. Autoantibodies generated by patients with systemic sclerosis are uniquely targeted to nucleolar proteins ..
  13. Role of T Cells in Lung Disease in Systemic Sclerosis
    Marc C Hochberg; Fiscal Year: 2006
    ..The new information that is gained will advance knowledge of T-cell dependent mechanisms of pulmonary fibrosis in scleroderma...
  14. Fibroblast TGF-beta/Smad Signaling in Scleroderma
    John Varga; Fiscal Year: 2006
    DESCRIPTION (provided by applicant): In systemic sclerosis (SSc), excessive accumulation of collagen leads to fibrosis and subsequent dysfunction of skin and internal organs...
  15. Role of TGF-beta and CTGF Signaling Transgenic Mouse Models of Scleroderma
    BENOIT DE CROMBRUGGHE; Fiscal Year: 2008
    Scleroderma or systemic sclerosis (SSc) is a disorder of the connective tissues affecting various organ systems...
  16. Mechanisms of Tolerance to Renal Maternal Microchimerism
    Anne M Stevens; Fiscal Year: 2008
    ..levels of fetal and maternal microchimerism (MMc) have been found within blood and tissues of patients with systemic sclerosis, SLE, and dermatomyositis. However, microchimerism is also common in healthy individuals...
  17. Mechanisms of Tolerance to Renal Maternal Microchimerism
    Anne M Stevens; Fiscal Year: 2007
    ..levels of fetal and maternal microchimerism (MMc) have been found within blood and tissues of patients with systemic sclerosis, SLE, and dermatomyositis. However, microchimerism is also common in healthy individuals...
  18. Microarray biomarkers of disease activity and progression in systemic sclerosis
    ROBERT A LAFYATIS; Fiscal Year: 2007
    ....
  19. Fine specificity of scleroderma autoantibodies
    Judith A James; Fiscal Year: 2005
    DESCRIPTION (provided by applicant): Systemic sclerosis (scleroderma) is a disfiguring, multi-system disease of unknown etiology, which is characterized by a broad spectrum of disease manifestations with varying organ involvement...
  20. Molecular Determinants of Pulmonary Arterial Hypertension
    Paul M Hassoun; Fiscal Year: 2008
    ..applicant): Pulmonary arterial hypertension (PAH) is a devastating syndrome, particularly for patients with systemic sclerosis (SSc), leading almost uniformly to death through right ventricular (RV) failure...
  21. Molecular Determinants of Pulmonary Arterial Hypertension
    Paul M Hassoun; Fiscal Year: 2007
    ..applicant): Pulmonary arterial hypertension (PAH) is a devastating syndrome, particularly for patients with systemic sclerosis (SSc), leading almost uniformly to death through right ventricular (RV) failure...
  22. Inflammation, fibrosis and myocardial function in schleroderma
    Dorothee Weihrauch; Fiscal Year: 2008
    ..excess cytokine production, fibrosis and subsequent myocardial dysfunction and heart failure in systemic scleroderma. Based on preliminary data we will use an ApoAl mimetic, D-4F, to improve fibrosis, myocardial function and ..
  23. Study of Persistent Infection in SSc Skin and Vessels
    Maureen D Mayes; Fiscal Year: 2002
    ..Specific aims are: (1) to test skin biopsies from 60 systemic scleroderma patients and 30 matched normal controls for evidence of bacterial persistence by pan-bacterial and ..
  24. ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS
    Charles Read; Fiscal Year: 2003
    In Systemic Sclerosis (SSc), interstitial pulmonary fibrosis is frequent (80%) and is now the leading cause of death. The mortality rate of patients with a forced vital capacity (FVC) 3.0% neutrophils or equal to or >2...
  25. ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS
    Dean E Schraufnagel; Fiscal Year: 2003
    In Systemic Sclerosis (SSc), interstitial pulmonary fibrosis is frequent (80%) and is now the leading cause of death. The mortality rate of patients with a forced vital capacity (FVC) 3.0% neutrophils or equal to or >2...
  26. INHIBITION OF MONOCYTE TGFB1-INDUCED SKIN FIBROSIS
    Anita C Gilliam; Fiscal Year: 2002
    ..The proposal involves the study of systemic sclerosis/scleroderma, a chronic autoimmune disease of unknown etiology characterized by altered humoral and cell-..
  27. DIFFERENTIAL GENE EXPRESSION IN SCLERODERMA FIBROBLASTS
    Joseph H Korn; Fiscal Year: 2002
    The underlying basis of systemic sclerosis, scleroderma, is unknown. Cultured dermal fibroblasts from scleroderma patients overexpress extracellular matrix components, thus retaining a feature of scleroderma skin in the culture model...
  28. SCLERODERMA LUNG STUDY
    Robert A Wise; Fiscal Year: 2003
    In Systemic Sclerosis (SSc), interstitial pulmonary fibrosis is frequent (80%) and is now the leading cause of death. The mortality rate of patients with a forced vital capacity (FVC) 3.0% neutrophils or equal to or >2...
  29. SCLERODERMA LUNG STUDY
    Richard M Silver; Fiscal Year: 2003
    In Systemic Sclerosis (SSc), interstitial pulmonary fibrosis is frequent (80%) and is now the leading cause of death. The mortality rate of patients with a forced vital capacity (FVC) 3.0% neutrophils or equal to or >2...
  30. SCLERODERMA LUNG STUDY
    David J Riley; Fiscal Year: 2003
    In Systemic Sclerosis (SSc), interstitial pulmonary fibrosis is frequent (80%) and is now the leading cause of death. The mortality rate of patients with a forced vital capacity (FVC) 3.0% neutrophils or equal to or >2...
  31. Scleroderma Lung Study
    Donald P Tashkin; Fiscal Year: 2003
    In Systemic Sclerosis (SSc), interstitial pulmonary fibrosis is frequent (80%) and is now the leading cause of death. The mortality rate of patients with a forced vital capacity (FVC) 3.0% neutrophils or equal to or >2...
  32. SCLERODERMA LUNG STUDY
    Arthur C Theodore; Fiscal Year: 2003
    In Systemic Sclerosis (SSc), interstitial pulmonary fibrosis is frequent (80%) and is now the leading cause of death. The mortality rate of patients with a forced vital capacity (FVC) 3.0% neutrophils or equal to or >2...
  33. SCLERODERMA LUNG STUDY
    Robert M Elashoff; Fiscal Year: 2006
    In Systemic Sclerosis (SSc), interstitial pulmonary fibrosis is frequent (80%) and is now the leading cause of death. The mortality rate of patients with a forced vital capacity (FVC) 3.0% neutrophils or equal to or >2...
  34. SCLERODERMA LUNG STUDY
    Maureen D Mayes; Fiscal Year: 2003
    In Systemic Sclerosis (SSc), interstitial pulmonary fibrosis is frequent (80%) and is now the leading cause of death. The mortality rate of patients with a forced vital capacity (FVC) 3.0% neutrophils or equal to or >2...
  35. Experimental models of scleroderma pathogenesis
    FRANCESCO B RAMIREZ; Fiscal Year: 2008
    ..Scleroderma (Systemic Sclerosis; SSc) is a clinically heterogeneous and poorly understood disorder of the connective tissue that is ..
  36. Immunological Mechanisms in Systemic Autoimmune Disease
    Ann Marshak-Rothstein; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Systemic Sclerosis (SSc) can be a chronic life threatening autoimmune disorder associated with severe vascular damage and fibrosis of the skin and/or internal organs...
  37. Biomarkers of Vascular Disease in Scleroderma
    Laura K Hummers; Fiscal Year: 2008
    ..b>Systemic sclerosis is a multisystem disease manifested by cutaneous fibrosis, vascular abnormalities and immunological ..
  38. Biomarkers of Vascular Disease in Scleroderma
    Laura K Hummers; Fiscal Year: 2007
    ..b>Systemic sclerosis is a multisystem disease manifested by cutaneous fibrosis, vascular abnormalities and immunological ..
  39. Pathogenic Mechanisms of Fibrosis:Common Ground
    Arnold E Postlethwaite; Fiscal Year: 2004
    ..arthritic, musculoskeletal and skin diseases such as systemic lupus, erythematosus, rheumatoid arthritis, systemic sclerosis (scleroderma) and morphea. This symposium addresses important topics related to the NtAMS mission...
  40. Health Values and Minimally Important Differences in Systemic Sclerosis
    Dinesh Khanna; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Systemic Sclerosis (Scleroderma, SSc) is a chronic rheumatic disease with no effective treatment or cure, in which patients cope with pain, disfigurement, disability, and feelings of helplessness, each ..
  41. Health Values and Minimally Important Differences in Systemic Sclerosis
    Dinesh Khanna; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): Systemic Sclerosis (Scleroderma, SSc) is a chronic rheumatic disease with no effective treatment or cure, in which patients cope with pain, disfigurement, disability, and feelings of helplessness, each ..
  42. CYTOKINES AS PREDICTORS OF DISEASE PROGRESSION IN SCLERODERMA LUNG DISEASE
    Michael D Roth; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Pulmonary fibrosis is the leading cause of death in systemic sclerosis (SSc)...
  43. Pregnancy, Microchimerism, and Autoimmune Disease
    J Lee Nelson; Fiscal Year: 2008
    ..This grant began with investigative studies of the autoimmune disease systemic sclerosis (SSc). Excess fetal- maternal HLA-sharing was found in women with SSc compared to healthy women...
  44. HLA Alleles, Self-Peptides and Microbial Mimicry in SSc
    J Lee Nelson; Fiscal Year: 2005
    ..that HLA alleles, HLA self-peptides and microbial mimicry, in concert, contribute to the pathogenesis of systemic sclerosis (SSc)...
  45. Pregnancy, Microchimerism, and Autoimmune Disease
    J Lee Nelson; Fiscal Year: 2007
    ..This grant began with investigative studies of the autoimmune disease systemic sclerosis (SSc). Excess fetal- maternal HLA-sharing was found in women with SSc compared to healthy women...
  46. CHEMOKINE REGULATION OF NKT CELLS, AND ACAID
    JOAN E STEIN-STREILEIN; Fiscal Year: 2003
    ..is associated with a variety of autoimmune disorders in both mice and humans (lupus, type 1 diabetes, systemic scleroderma)...
  47. Molecular Mechanisms of Fibrosis: From Bench to Bedside
    Andrew D Robertson; Fiscal Year: 2007
    ..and mortality include the interstitial lung diseases, liver cirrhosis, kidney disease, heart disease, and systemic sclerosis, among others...
  48. Fibroblast TGF-beta/Signaling in Scleroderma: Modulation by PPAR-gamma
    John Varga; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) is a devastating condition with no disease-modifying treatment...
  49. CHARACTERIZING MICROFIBRIL ABNORMALITIES IN SCLERODERMA
    Dianna M Milewicz; Fiscal Year: 2003
    Progressive fibrosis of the skin and internal organs is the pathologic hallmark of scleroderma or systemic sclerosis (SSc). The etiology of SSc is unknown but both genetic and environmental factors have been proposed...
  50. Center for Research Translation in Scleroderma
    Frank C Arnett; Fiscal Year: 2008
    ..Public Health (Human Genetics Center) propose to establish a Center of Research Translation in Scleroderma (systemic sclerosis or SSc) or UTHCORT- SSc. The Director will be Frank C. Arnett, M.D. and the Associate Director Maureen D...
  51. CYTOKINES AS PREDICTORS OF DISEASE PROGRESSION IN SCLERODERMA LUNG DISEASE
    Michael D Roth; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): Pulmonary fibrosis is the leading cause of death in systemic sclerosis (SSc)...
  52. CYTOKINES AS PREDICTORS OF DISEASE PROGRESSION IN SCLERODERMA LUNG DISEASE
    Michael P Keane; Fiscal Year: 2006
    DESCRIPTION (provided by applicant): Pulmonary fibrosis is the leading cause of death in systemic sclerosis (SSc)...
  53. TSK-2: A NEW ANIMAL MODEL FOR SCLERODERMA
    Paul J Christner; Fiscal Year: 2004
    b>Systemic sclerosis (SSc) is a serious disease of unknown cause, characterized by excessive accumulation of collagen and other connective tissue components in the skin and internal organs...
  54. Self-and Foreign-Lipids Presented by CD1 in Scleroderma
    Michael S Vincent; Fiscal Year: 2003
    ..a role in host defense, immune tolerance, tumor immunity, and autoimmune disease such as systemic lupus, systemic sclerosis, and type I diabetes...
  55. PSYCHOSOCIAL INTERVENTIONS FOR SCLERODERMA
    Jennifer A Haythornthwaite; Fiscal Year: 2003
    DESCRIPTION (adapted from investigator's abstract): Systemic sclerosis (scleroderma: SSc) is a rare, disfiguring connective tissue disease characterized by inflammation vascular injury, and fibrosis...
  56. Mechanisms of Resistance to Apoptosis in Scleroderma Skin Fibroblasts
    Nora Sandorfi; Fiscal Year: 2007
    ..Sandorfi is a rheumatologist with keen interest in clinical and basic research specifically related to systemic sclerosis (SSc)...
  57. Provisional Combined Response Index For Patients With Diffuse Systemic Sclerosis
    DANIEL ERIC FURST; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Systemic sclerosis Scleroderma, (SSc) can be associated with a high morbidity and mortality...
  58. Biochemical and Vascular Alterations in Scleroderma
    Sergio A Jimenez; Fiscal Year: 2008
    DESCRIPTION (provided by applicant): Scleroderma or Systemic Sclerosis (SSc) is a disease of unknown etiology characterized by the excessive deposition of collagen and other connective tissue components in skin and multiple internal ..
  59. Provisional Combined Response Index For Patients With Diffuse Systemic Sclerosis
    DANIEL ERIC FURST; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): Systemic sclerosis Scleroderma, (SSc) can be associated with a high morbidity and mortality...
  60. Nonmyeloablative Hematopoietic Cell Transplantation for Severe Systemic Sclerosis
    Richard A Nash; Fiscal Year: 2006
    DESCRIPTION (provided by applicant): Severe systemic sclerosis (SSc) is a potentially fatal autoimmune disease. For patients with diffuse cutaneous SSc with internal organ involvement, 5-year survival is approximately 50%...
  61. Gradient-Enhanced FAWSETS Perfusion Measurements in Skeletal Muscle
    Kenneth I Marro; Fiscal Year: 2007
    ..diseases, including insulin resistance and diabetes, congestive heart failure, compartment syndrome, PAD and systemic sclerosis. These diseases are serious public health issues that increase medical costs and reduce the quality of life ..
  62. Multidisciplinary Clinical Research Center
    Robert P Kimberly; Fiscal Year: 2006
    ..Clinical research in RA, SLE, OA, systemic sclerosis, fibromyalgia, Wegener's granulomatosis, and osteoporosis will be leveraged through the expertise of the ..

Publications62

  1. [Pulmonary arterial hypertension in connective tissue disease]
    V Cottin
    Service de Pneumologie, Centre de référence des maladies orphelines pulmonaires, Hôpital Louis Pradel, Hospices Civils de Lyon, Université de Lyon, UMR 754 INRA ENVL UCBL IFR128, Lyon, France
    Rev Mal Respir 23:13S61-72
    ..PAH may be observed in any of the connective tissue diseases; it is mostly encountered in systemic sclerosis (prevalence estimated to 8%), and is more frequent in the limited form of the disease with anticentromeres ..
  2. Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis
    M Hasegawa
    Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13 1 Takaramachi, Kanazawa, Ishikawa 920 8641, Japan
    Ann Rheum Dis 63:1514-7
    ..frequency and clinical association of antiphosphatidylserine-prothrombin complex (PS/PT) antibody (Ab) in systemic sclerosis (SSc)...
  3. Acute congestive heart failure associated with a limited form of systemic sclerosis and primary biliary cirrhosis
    T Shinohara
    Internal Medicine I, National Defense Medical College, Tokorozawa, Saitama
    Intern Med 40:73-6
    This is the first case of a limited form of systemic sclerosis (ISSc) associated with acute congestive heart failure (CHF) and primary biliary cirrhosis (PBC). A 58-year-old woman with ISSc was admitted because of a sudden onset of CHF...
  4. Increased but imbalanced expression of VEGF and its receptors has no positive effect on angiogenesis in systemic sclerosis skin
    Z Mackiewicz
    Institute of Experimental and Clinical Medicine, Vilnius, Lithuania
    Clin Exp Rheumatol 20:641-6
    ..expression of vascular endothelial growth factor (VEGF) and its vascular and lymphatic receptors in skin in systemic sclerosis (SSc) compared to systemic lupus erythematosus (SLE), Raynaud's phenomenon (RP) and normal healthy control ..
  5. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis
    C Nishijima
    Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
    Clin Exp Immunol 138:357-63
    b>Systemic sclerosis (SSc) is characterized by multi-organ fibrosis with an autoimmune background. Although autoantibodies are detected frequently in SSc patients, the role of autoantibody in the development of fibrosis remains unknown...
  6. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma
    Ayumi Yoshizaki
    Department of Dermatology, Nagasaki University Graduate School of Biomedical Sciences, 1 7 1 Sakamoto, Nagasaki, 852 8501, Japan
    Am J Pathol 172:1650-63
    Mice subcutaneously injected with bleomycin, in an experimental model of human systemic sclerosis, develop cutaneous and lung fibrosis with autoantibody production...
  7. [Pathogenesis of systemic sclerosis]
    M Fabri
    Klinik und Poliklinik für Dermatologie und Venerologie, Universität zu Köln, Kerpenerstrasse 62, 50924, Köln, Germany
    Hautarzt 58:838, 840-3
    b>Systemic sclerosis is a complex multi-systemic disease with a mostly unresolved pathogenesis. Following an inflammatory reaction, overproduction of collagen and other extra-cellular matrix components leads to a characteristic fibrosis...
  8. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years
    L Bettoni
    Servizio di Reumatologia ed Immunologia Clinica, Spedali Civili and University, I-25124 Brescia, Italy
    Clin Rheumatol 21:244-50
    ..is useful in the short-term treatment of severe Raynaud's phenomenon and ischaemic ulcers in patients with systemic sclerosis (SSc), but its long-term effects are largely unknown...
  9. [Fourier transform spectral analysis of cutaneous blood flux in systemic sclerosis]
    M Salvat Melis
    Laboratoire HP2 EA 3745, Inserm ERI 017, université de Grenoble 1 EA 3745, CHU de Grenoble, 38043 Grenoble Cedex 09, France
    J Mal Vasc 32:83-9
    OBJECTIVES: Endothelial dysfunction is an early event and a critical step in the pathogenesis of systemic sclerosis. Accurate and sensitive tests are needed to correctly assess the degree of microvascular endothelial dysfunction...
  10. [Antiphospholipid syndrome in patients with systemic connective tissue diseases]
    Dalia Unikiene
    Clinic of Rheumatology, Kaunas University of Medicine, Lithuania
    Medicina (Kaunas) 39:454-9
    ..consecutive patients suffering from rheumatoid arthritis (158 pts), systemic erythematoid lupus (53 pts), or systemic sclerosis (31 pts) are studied...
  11. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis
    Yasushi Kawaguchi
    Institute of Rheumatology, Tokyo Women s Medical University School of Medicine, Japan
    J Rheumatol 29:1877-83
    ..induction of hepatocyte growth factor (HGF)/c-met signaling in fibroblasts derived from patients with systemic sclerosis (SSc). METHODS: Fibroblasts were obtained from skin of patients with SSc and healthy controls. The 2...
  12. A novel protein highly expressed in testis is overexpressed in systemic sclerosis fibroblasts and targeted by autoantibodies
    Hidekata Yasuoka
    Department of Internal Medicine and Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan
    J Immunol 171:6883-90
    Nearly all autoantibody specificities in sera from patients with systemic sclerosis (SSc) target proteins distributed ubiquitously, and Abs against proteins whose expression is restricted to the affected sites have not been identified...
  13. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis
    A Servettaz
    Université Paris Descartes, Faculté de Médecine, IFR Alfred Jost, Paris, France, and Service de Médecine Interne, Centre National de Référence Sclérodermie Vascularites, AP HP, Hôpital Cochin, Paris, France
    Ann Rheum Dis 66:1202-9
    ..To investigate the role of reactive oxygen species (ROS) in the development of the various patterns of systemic sclerosis (SSc) and the mechanisms of ROS production by endothelial cells and fibroblasts...
  14. Digital thermal hyperaemia impairment does not relate to skin fibrosis or macrovascular disease in systemic sclerosis
    M Salvat-Melis
    INSERM ESPRI HP2 Laboratory, Grenoble Medical School, Grenoble University Hospital, Grenoble, France
    Rheumatology (Oxford) 45:1490-6
    OBJECTIVES: Thermal hyperaemia is impaired in patients with systemic sclerosis (SSc). The objective of these studies was to determine whether this was consecutive to skin fibrosis, microangiopathy or macroangiopathy...
  15. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis
    Yuval Bibi
    Department of Dermatology at Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Am Acad Dermatol 59:654-8
    ..b>Systemic sclerosis (SS) is a recalcitrant disease featuring multiorgan fibrosis and dysfunction...
  16. Early impairment of myocardial function in systemic sclerosis: non-invasive assessment by Doppler myocardial and strain rate imaging
    Stefano Stisi
    Department of Interventional Cardiology, G Rummo Hospital, Benevento, Italy
    Eur J Echocardiogr 6:407-18
    ..present study was to analyze both left (LV) and right ventricular (RV) myocardial function in patients with Systemic Sclerosis (SSc), and their relation to other instrumental features of the disease...
  17. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension
    Benjamin Terrier
    Laboratoire d Immunologie, UPRES EA 4058, Pavillon Gustave Roussy, 4e étage, Paris Descartes University, 8 rue Méchain, 75014 Paris, France
    Am J Respir Crit Care Med 177:1128-34
    ..FPAH) or associated with various conditions and exposures such as dexfenfluramine intake (Dex-PAH) or systemic sclerosis (SSc-PAH)...
  18. [Tumor necrosis factor alpha in systemic scleroderma]
    R T Alekperov
    Klin Med (Mosk) 81:4-7
    ..SS patients exhibit a systemic and local rise of TNF alpha content. This rise contributes to SS progression, development of fibrosing alveolitis and skin fibrous alterations in Raynaud's syndrome...
  19. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis
    Olivier C Meyer
    Rheumatology Unit, Bichat Hospital, Paris, France
    J Rheumatol 34:104-9
    OBJECTIVE: To investigate the specificities of antinuclear antibodies (ANA) associated with systemic sclerosis (SSc) disease classification and internal organ involvement among patients with SSc of different origins (European and American)..
  20. Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients
    J Avouac
    René Descartes University, Medical Faculty, Hôpital Cochin, France
    Arthritis Rheum 54:2243-9
    ..prevalence of sicca symptoms and Sjögren's syndrome (SS) in a 2-center prospective series of patients with systemic sclerosis (SSc), using the American-European Consensus Group criteria for SS...
  21. A juvenile case of overlap syndrome of systemic lupus erythematosus and polymyositis, later accompanied by systemic sclerosis with the development of anti-Scl 70 and anti-Ku antibodies
    Y Nitta
    Department of Dermatology, Aichi Medical University, Japan
    Pediatr Dermatol 17:381-3
    ..lupus erythematosus (SLE) from the age of 7 and polymyositis (PM) from the age of 10, later accompanied by systemic sclerosis (SSc) from the age of 15...
  22. Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features
    K Takagi
    Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
    Clin Exp Immunol 134:538-44
    Vascular damage in systemic sclerosis (SSc) may be a factor in the abnormal regulation of several vasoactive agents. It has been well confirmed that plasma endothelin-1, as a vasoconstrictive factor, is elevated in patients with SSc...
  23. Increased prevalence of human parvovirus B19 DNA in systemic sclerosis skin
    T Ohtsuka
    Department of Dermatology, Dokkyo Koshigaya Hospital, 2 1 50, Saitoma, 343 8555, Japan
    Br J Dermatol 150:1091-5
    ..In recent years, the possible involvement of parvovirus B19 in systemic sclerosis (SSc) has been reported...
  24. Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis
    Mo Yin Mok
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong
    J Rheumatol 34:2224-9
    ..antiinflammatory properties, may have a regulatory role in the vascular manifestations of scleroderma (systemic sclerosis, SSc)...
  25. Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement
    I Moyssakis
    Laikon Hospital, Department of Cardiology, 17 Agiou Thomas Street, GR-15727 Goudi, Athens, Greece
    Rheumatology (Oxford) 44:251-4
    ..extent of skin and lung fibrosis, aortic distensibility was examined in patients with diffuse and limited systemic sclerosis (SSc)...
  26. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin
    Masahide Kubo
    Division of Rheumatology and Immunology and the Laboratory of Cancer Genomics, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Am J Pathol 163:571-81
    ..cells in clinically involved scleroderma skin, which correlates with enhanced collagen synthesis in systemic sclerosis skin. This study supports the role of Fli1 as a suppressor of collagen transcription in human skin in vivo...
  27. Fibroblast expression of the coactivator p300 governs the intensity of profibrotic response to transforming growth factor beta
    Swati Bhattacharyya
    Northwestern University, Chicago, Illinois
    Arthritis Rheum 52:1248-58
    ..in normal fibroblasts, and plays a fundamental role in the pathogenesis of fibrosis in scleroderma (systemic sclerosis [SSc])...
  28. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors
    Yasushi Kawaguchi
    Tokyo Women s Medical University School of Medicine, Tokyo, Japan
    Arthritis Rheum 50:216-26
    OBJECTIVE: Tissue fibrosis in systemic sclerosis (SSc) is attributed to excessive deposition of extracellular matrix components produced by fibroblasts in skin lesions...
  29. Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse
    Voon H Ong
    Royal Free Hospital and University College Medical School, London, UK
    Arthritis Rheum 48:1979-91
    ..and potential fibrotic activity of monocyte chemoattractant protein 3 (MCP-3) in Tsk1 mouse and human systemic sclerosis (SSc) skin. METHODS: Complementary DNA microarrays (Atlas 1...
  30. Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma
    Swati Bhattacharyya
    Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Am J Pathol 173:1085-99
    ....
  31. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis
    Vineeth S Rajkumar
    Centre for Rheumatology and Connective Tissue Disease, Department of Medicine, Royal Free Campus, University College London, London, UK
    Arthritis Res Ther 7:R1113-23
    The mechanisms by which microvascular damage leads to dermal fibrosis in diffuse cutaneous systemic sclerosis (dcSSc) are unclear...
  32. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts
    Yasuji Mori
    University of Illinois at Chicago College of Medicine, Chicago, IL 60607, USA
    Arthritis Rheum 48:1964-78
    ..SMAD signaling may be a mechanism contributing to the characteristic phenotype of scleroderma fibroblasts and playing a role in the pathogenesis of fibrosis...
  33. Clinical characteristics of Japanese patients with anti-PL-7 (anti-threonyl-tRNA synthetase) autoantibodies
    S Sato
    Department of Internal Medicine, Keio University, School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, Japan
    Clin Exp Rheumatol 23:609-15
    ..The clinical diagnoses of these seven patients were PM - systemic sclerosis (SSc) overlap (5 patients), DM (1 patient) and idiopathic pulmonary fibrosis (IPF) (1 patient)...
  34. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement
    Virginia Steen
    Georgetown University Medical Center, Division of Rheumatology, Immunology and Allergy, Department of Medicine, Gorman LL Building, 3800 Reservoir NW, Washington, DC 20007, USA
    Arthritis Rheum 48:516-22
    ..The long-term use of calcium channel blockers may be protective, but newer agents that are more effective in treating PHT may also be helpful in altering the natural history of this serious complication in limited scleroderma...
  35. Autoantibodies against cytoskeletal proteins in rheumatoid arthritis
    M Shrivastav
    Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
    Clin Rheumatol 21:505-10
    ..Sera collected from patients with rheumatoid arthritis, systemic lupus erythematosus or progressive systemic sclerosis, and normal volunteers, were examined for the presence of autoantibodies against cytoskeletal proteins by ..
  36. Identification of an autoimmune serum containing antibodies against the Barr body
    B Hong
    Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville, FL 32610, USA
    Proc Natl Acad Sci U S A 98:8703-8
    ..This demonstration of an autoantibody recognizing an antigen(s) associated with the Barr body presents a strategy for identifying molecular components of the Barr body and examining the molecular basis of X inactivation...
  37. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease
    K Ahmadi Simab
    Department of Rheumatology, University Hospital of Schleswig Holstein, Campus Lübeck and Rheumaklinik Bad Bramstedt, Germany
    Eur J Clin Invest 36:44-8
    ..ET is believed to be a key pathogenic mediator in systemic sclerosis (scleroderma, SSc), causing fibrotic, hypertrophic and inflammatory processes...
  38. Autoantibody response against a novel testicular antigen protein highly expressed in testis (PHET) in SSc patients
    Hidekata Yasuoka
    Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh School of Medicine, 3459 Fifth Avenue NW628 MUH, Pittsburgh, PA 15213, USA
    Autoimmun Rev 6:228-31
    b>Systemic sclerosis (SSc) is characterized by excessive fibrosis and autoantibody production. However, the pathogenesis of SSc is still under investigation...
  39. Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice
    R G Phelps
    Department of Microbiology, Mount Sinai School of Medicine, New York, NY 10029 6574
    J Autoimmun 6:701-18
    ..Our results strongly demonstrate, for the first time, that immunocompetent cells can play a role in the activation of collagen synthesis leading to skin fibrosis...
  40. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database
    Giorgia Martini
    University of Padua, Padua, Italy
    Arthritis Rheum 54:3971-8
    OBJECTIVE: To determine the clinical and immunologic features of systemic sclerosis (SSc) in a large group of children and describe the clinical evolution of the disease and compare it with the adult form...
  41. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database
    U A Walker
    Department of Rheumatology, Basle University, Felix Platter Spital, Burgfelderstrasse 101, Basel 4012, Switzerland
    Ann Rheum Dis 66:754-63
    BACKGROUND: Systemic sclerosis (SSc) is a multisystem autoimmune disease, which is classified into a diffuse cutaneous (dcSSc) and a limited cutaneous (lcSSc) subset according to the skin involvement...
  42. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis
    Minoru Hasegawa
    Department of Dermatology, Kanazawa University Graduate School of Medical Science, Japan
    Am J Pathol 169:954-66
    b>Systemic sclerosis (scleroderma) is an autoimmune disease characterized by excessive extracellular matrix deposition in the skin...
  43. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse
    Noriko Asano
    Department of Regenerative Medicine, Research Institute, International Medical Center of Japan, Tokyo, Japan
    Am J Pathol 165:641-50
    b>Systemic sclerosis (SSc) is characterized by fibrosis and autoimmmunity. Peripheral blood B cells from SSc patients specifically overexpress CD19, a critical cell-surface signal transduction molecule in B cells...
  44. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse
    K Komura
    Department of Dermatology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
    Ann Rheum Dis 67:867-72
    ..development of skin fibrosis and autoimmunity in tight-skin (TSK/+) mouse, which is a mouse model for human systemic sclerosis. METHODS: Newly born TSK/+ mice were treated with murine anti-CD40L monoclonal antibody (100 microg ..
  45. Mercuric chloride induces a strong immune activation, but does not accelerate the development of dermal fibrosis in tight skin 1 mice
    M Hansson
    Department of Immunology, The Wenner-Gren Institute, Arrhenius Laboratories for the Natural Sciences, Stockholm University, Stockholm, Sweden
    Scand J Immunol 59:469-77
    ..Thus, exposure to mercury accelerates the immune dysregulation, but not the development of skin fibrosis in Tsk1/+ mice...
  46. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement
    Ghaith M Mitri
    HealthStar Physicians, Jefferson City, Tennessee, USA
    Arthritis Rheum 48:203-9
    ..To compare anti-Th/To-positive and anticentromere antibody (ACA)-positive patients with limited cutaneous systemic sclerosis (lcSSc)...
  47. [Dysthyroidism and connective pathology]
    I Schachter
    UOC di Angiologia, Azienda Ospedaliera S. Giovanni-Addolorata, Roma
    Minerva Cardioangiol 54:811-4
    ....
  48. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis
    M Cutolo
    Research Laboratory and Division of Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy
    Rheumatology (Oxford) 43:719-26
    BACKGROUND: Microvascular lesions are a predominant feature in systemic sclerosis (SSc) and seem to play a central pathogenetic role...
  49. Spontaneous chromosome damage (micronuclei) in systemic sclerosis and Raynaud's phenomenon
    Giovanni Porciello
    Istituto di Reumatologia, University of Siena, Italy
    J Rheumatol 30:1244-7
    ..evaluate the prevalence of spontaneous chromosome damage in cultured peripheral lymphocytes of patients with systemic sclerosis (SSc), idiopathic Raynaud's phenomenon (RP), and suspected secondary RP, by means of molecular cytogenetic ..
  50. Antibodies to beta2 glycoprotein I and cardiolipin in SSc
    L Schoenroth
    Ann Rheum Dis 61:183-4
  51. Juvenile systemic sclerosis: a follow-up study of eight patients
    Szilvia Szamosi
    Third Department of Medicine, Division of Rheumatology, University of Debrecen Medical Center, 22 Moricz Zs Street, Debrecen, H-4004, Hungary
    Ann N Y Acad Sci 1051:229-34
    Juvenile systemic sclerosis (jSSc) is a rare form of systemic sclerosis (also known as scleroderma). Fewer than 10% of SSc cases have their onset before age 20 and fewer than 2% before the age of 10...
  52. [Systemic sclerosis--a challenge in rheumatology]
    P Saar
    Abt für Rheumatologie und klinische Immunologie, Lehrstuhl für Innere Medizin mit Schwerpunkt Rheumatologie der Justus Liebig Universität Giessen, Kerckhoff Klinik, Bad Nauheim
    Z Rheumatol 65:429-38; quiz 439-40
    The connective tissue disease systemic sclerosis (SSc) is still a challenge to every rheumatologist...
  53. New developments in the pathogenesis of systemic sclerosis
    Lazaros I Sakkas
    Thessaly University School of Medicine, Larisa 412 22, Greece
    Autoimmunity 38:113-6
    b>Systemic sclerosis (SSc) is characterized by extensive fibrosis, vasculopathy and activation of the immune system...
  54. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon
    Stephan Rosenkranz
    Ann Intern Med 139:871-3
  55. Pulmonary arterial hypertension in Thai patients with systemic sclerosis
    Suparaporn Wangkaew
    Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
    J Med Assoc Thai 91:166-72
    OBJECTIVE: Study the clinical features of pulmonary arterial hypertension (PAH) in Thai patients with systemic sclerosis (SSc), and compare these features between those with limited (lc) SSc and diffuse (dc) SSc...
  56. [Diagnosis and therapy for systemic sclerosis]
    Hisanori Umehara
    Nippon Naika Gakkai Zasshi 96:2165-70